Felli James (28 results)
More imagesLanguage: English
Published by Chapman and Hall/CRC Press, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: Salish Sea Books, Bellingham, WA, U.S.A.Salish Sea Books
Contact seller5-star sellerCondition: Used - Very good
US$ 59.95
US$ 4.99 shippingShips within U.S.A.Quantity: 1 available
Condition: Very Good. Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardboard box with foam padd…ing; Medium Format (8.5" - 9.75" tall); Dark blue and aqua covers with title in white lettering; 2013, Chapman and Hall/CRC Press; 220 pages; "Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)," by Andreas Sashegyi, et al.
Benefit-risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (EDT); Felli, James (EDT); Noel, Rebecca (EDT)
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: Used - As new
US$ 72.14
US$ 2.64 shippingShips within U.S.A.Quantity: 1 available
Condition: As New. Unread book in perfect condition.
Benefit-risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (EDT); Felli, James (EDT); Noel, Rebecca (EDT)
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: New
US$ 81.07
US$ 2.64 shippingShips within U.S.A.Quantity: 1 available
Condition: New.
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: Majestic Books, Hounslow, United KingdomMajestic Books
Contact seller4-star sellerCondition: New
US$ 75.01
US$ 8.72 shippingShips from United Kingdom to U.S.A.Quantity: 3 available
Condition: New. pp. 220.
More imagesLanguage: English
Published by Chapman and Hall/CRC, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: Salish Sea Books, Bellingham, WA, U.S.A.Salish Sea Books
Contact seller5-star sellerCondition: Used - Very good
US$ 79.95
US$ 4.99 shippingShips within U.S.A.Quantity: 1 available
Hardcover. Condition: Very Good. 1439867941 Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardbo…ard box with foam padding; Medium Format (8.5" - 9.75" tall); Aqua and blue covers with title in white lettering; 2013, Chapman and Hall/CRC; 220 pages; "Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)," by Andreas Sashegyi, et al.
Language: English
Published by CRC Press, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: PBShop.store UK, Fairford, GLOS, United KingdomPBShop.store UK
Contact seller5-star sellerCondition: New
US$ 88.85
US$ 6.73 shippingShips from United Kingdom to U.S.A.Quantity: Over 20 available
PAP. Condition: New. New Book. Shipped from UK. Established seller since 2000.
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: Books Puddle, New York, NY, U.S.A.Books Puddle
Contact seller4-star sellerCondition: New
US$ 90.26
US$ 3.99 shippingShips within U.S.A.Quantity: 3 available
Condition: New. pp. 220.
Benefit-risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (EDT); Felli, James (EDT); Noel, Rebecca (EDT)
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: GreatBookPricesUK, Woodford Green, United KingdomGreatBookPricesUK
Contact seller5-star sellerCondition: Used - As new
US$ 76.69
US$ 20.12 shippingShips from United Kingdom to U.S.A.Quantity: 1 available
Condition: As New. Unread book in perfect condition.
Language: English
Published by Taylor & Francis Inc, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: Studibuch, Stuttgart, GermanyStudibuch
Contact seller5-star sellerCondition: Used - Fine
US$ 23.93
US$ 71.23 shippingShips from Germany to U.S.A.Quantity: 1 available
hardcover. Condition: Sehr gut. 220 Seiten; 9781439867945.2 Gewicht in Gramm: 1.
Language: English
Published by Taylor & Francis Ltd, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: THE SAINT BOOKSTORE, Southport, United KingdomTHE SAINT BOOKSTORE
Contact seller5-star sellerCondition: New
US$ 80.26
US$ 19.89 shippingShips from United Kingdom to U.S.A.Quantity: 1 available
Paperback / softback. Condition: New. New copy - Usually dispatched within 4 working days.
Benefit-risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (EDT); Felli, James (EDT); Noel, Rebecca (EDT)
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: GreatBookPricesUK, Woodford Green, United KingdomGreatBookPricesUK
Contact seller5-star sellerCondition: New
US$ 80.25
US$ 20.12 shippingShips from United Kingdom to U.S.A.Quantity: 1 available
Condition: New.
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: Biblios, frankfurt am main, HESSE, GermanyBiblios
Contact seller4-star sellerCondition: New
US$ 92.32
US$ 11.38 shippingShips from Germany to U.S.A.Quantity: 3 available
Condition: New. pp. 220.
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: Ria Christie Collections, Uxbridge, United KingdomRia Christie Collections
Contact seller5-star sellerCondition: New
US$ 87.68
US$ 16.07 shippingShips from United Kingdom to U.S.A.Quantity: Over 20 available
Condition: New. In.
Benefit-risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (Editor)/ Felli, James (Editor)/ Noel, Rebecca (Editor)
Language: English
Published by Chapman & Hall, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
Contact seller5-star sellerCondition: New
US$ 110.35
US$ 13.41 shippingShips from United Kingdom to U.S.A.Quantity: 2 available
Paperback. Condition: Brand New. 220 pages. 9.25x6.14x0.51 inches. In Stock.
Language: English
Published by CRC Press, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: moluna, Greven, Germanymoluna
Contact seller5-star sellerCondition: New
US$ 66.92
US$ 56.01 shippingShips from Germany to U.S.A.Quantity: Over 20 available
Condition: New.
Benefit-Risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (EDT); Felli, James (EDT); Noel, Rebecca (EDT)
Language: English
Published by Chapman and Hall/CRC, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: Used - As new
US$ 131.83
US$ 2.64 shippingShips within U.S.A.Quantity: 10 available
Condition: As New. Unread book in perfect condition.
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
Seller: Mispah books, Redhill, SURRE, United KingdomMispah books
Contact seller4-star sellerCondition: New
US$ 118.81
US$ 33.53 shippingShips from United Kingdom to U.S.A.Quantity: 1 available
paperback. Condition: New. NEW. SHIPS FROM MULTIPLE LOCATIONS. book.
Benefit-Risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (EDT); Felli, James (EDT); Noel, Rebecca (EDT)
Language: English
Published by Chapman and Hall/CRC, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: New
US$ 147.54
US$ 2.64 shippingShips within U.S.A.Quantity: 10 available
Condition: New.
Benefit-Risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (EDT); Felli, James (EDT); Noel, Rebecca (EDT)
Language: English
Published by Chapman and Hall/CRC, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: GreatBookPricesUK, Woodford Green, United KingdomGreatBookPricesUK
Contact seller5-star sellerCondition: Used - As new
US$ 138.58
US$ 20.12 shippingShips from United Kingdom to U.S.A.Quantity: 10 available
Condition: As New. Unread book in perfect condition.
Language: English
Published by Taylor & Francis Group, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: Books Puddle, New York, NY, U.S.A.Books Puddle
Contact seller4-star sellerCondition: New
US$ 154.23
US$ 3.99 shippingShips within U.S.A.Quantity: 3 available
Condition: New. pp. 220.
Benefit-Risk Assessment in Pharmaceutical Research and Development
Sashegyi, Andreas (EDT); Felli, James (EDT); Noel, Rebecca (EDT)
Language: English
Published by Chapman and Hall/CRC, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: GreatBookPricesUK, Woodford Green, United KingdomGreatBookPricesUK
Contact seller5-star sellerCondition: New
US$ 144.90
US$ 20.12 shippingShips from United Kingdom to U.S.A.Quantity: 10 available
Condition: New.
Language: English
Published by Taylor & Francis Inc, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: THE SAINT BOOKSTORE, Southport, United KingdomTHE SAINT BOOKSTORE
Contact seller5-star sellerCondition: New
US$ 144.91
US$ 20.94 shippingShips from United Kingdom to U.S.A.Quantity: 1 available
Hardback. Condition: New. New copy - Usually dispatched within 4 working days.
Language: English
Published by Taylor & Francis Group, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: Biblios, frankfurt am main, HESSE, GermanyBiblios
Contact seller4-star sellerCondition: New
US$ 168.37
US$ 11.38 shippingShips from Germany to U.S.A.Quantity: 3 available
Condition: New. pp. 220.
Language: English
Published by CRC Press, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: moluna, Greven, Germanymoluna
Contact seller5-star sellerCondition: New
US$ 140.29
US$ 56.01 shippingShips from Germany to U.S.A.Quantity: Over 20 available
Gebunden. Condition: New.
Language: English
Published by Taylor & Francis Inc Nov 2013, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
Contact seller5-star sellerCondition: New
US$ 172.36
US$ 71.24 shippingShips from Germany to U.S.A.Quantity: 2 available
Buch. Condition: Neu. Neuware - Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provide…s a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment. The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule's journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies.The book also focuses on a molecule's entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety. Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.
Language: English
Published by Taylor & Francis Group, 2013
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Hardcover
- Print on Demand
Seller: Majestic Books, Hounslow, United KingdomMajestic Books
Contact seller4-star sellerCondition: New
US$ 141.51
US$ 8.72 shippingShips from United Kingdom to U.S.A.Quantity: 3 available
Condition: New. pp. 220 A 7 fig, 4-page color insert will appear of Figs. 5.10-5.16. follows page 96 This item is printed on demand.
Language: English
Published by Chapman and Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
- Print on Demand
Seller: preigu, Osnabrück, Germanypreigu
Contact seller5-star sellerCondition: New
US$ 96.62
US$ 80.03 shippingShips from Germany to U.S.A.Quantity: 5 available
Taschenbuch. Condition: Neu. Benefit-Risk Assessment in Pharmaceutical Research and Development | Andreas Sashegyi (u. a.) | Taschenbuch | Englisch | 2020 | Chapman and Hall/CRC | EAN 9780367576240 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on… Demand.
Language: English
Published by Chapman And Hall/CRC, 2020
Series: Chapman & Hall/CRC Biostatistics, Book 40 of 155. Book 40 of 155 - Chapman & Hall/CRC Biostatistics
- Softcover
- Print on Demand
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
Contact seller5-star sellerCondition: New
US$ 113.56
US$ 70.58 shippingShips from Germany to U.S.A.Quantity: 1 available
Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D, from early clinical dev…elopment to late-stage development to regulatory review to post-launch assessment. Suitable for those in b.
